Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021
Recruiting
Observational Study
Stage III Melanoma
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 221 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years;
* Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
* Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
* Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
…
Contacts